Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3457 Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms

Introduction: There are only few, but controversial data on the prognostic role of upfront primary tumor resection and mesenteric lymph node dissection (PTR) in patients with stage IV small intestinal neuroendocrine neoplasia (SI-NEN).

Conference:

Presenting Author:

Authors: Maurer E, Heinzel-Gutenbrunner M, Rinke A, Rütz J, Figiel J,

Keywords: stage 4 small intestine neuroendocrine neoplasm, primary tumor resection, survival, peptide receptor radionuclide therapy,

#2867 Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia

Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Markovich A, Kuznetsova A, Gorbunova V, Orel N, Emelianova G,

Keywords: neuroendocrine tumors, everolimus, uni- and multivariate analysis,

#352 Predictive factors of tumor control in patients with well differentiated digestive endocrine carcinomas (WDEC) treated with lanreotide

Introduction: The antiproliferative effect of somatostatin analogs was recently demonstrated.

Conference:

Presenting Author:

Authors: Palazzo M, Lombard-Bohas C, Cadiot G, Matysiak-Budnik T, Rebours V,

Keywords: somatostatin analogs, neuroendocrine, treatment, clinical,

#219 Predictive Factors of Tumor Control in Patients with Well-differentiated Digestive Endocrine Carcinomas (WDEC) Treated with Lanreotide

Introduction: Somatostatin analogues (SSA) are indicated in the control of secretory symptoms of digestive endocrine tumors. The antiproliferative effect of SSA was recently demonstrated (Rinke et al, JCO 2009).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Palazzo M, Catherine L, Guillaume C, Tamara M, Vinciane R,

Keywords: digestive endocrine tumors, lanreotide, tumor growth, Ki-67, liver metastases,